Search

Your search keyword '"Leung, Roland Ching-Yu"' showing total 21 results
Start Over Author "Leung, Roland Ching-Yu"
21 results on '"Leung, Roland Ching-Yu"'

1. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.

Author

Juric, Dejan, primary, Kalinsky, Kevin, additional, Turner, Nicholas C., additional, Jhaveri, Komal L., additional, Schmid, Peter, additional, Loi, Sherene, additional, Saura, Cristina, additional, Im, Seock-Ah, additional, Sunpaweravong, Patrapim, additional, Li, Huiping, additional, Musolino, Antonino, additional, Zhang, Qingyuan, additional, Nowecki, Zbigniew, additional, Leung, Roland Ching-Yu, additional, Thanopoulou, Eirini, additional, Shankar, Noopur, additional, Lei, Guiyuan, additional, Devine, Jacob, additional, Stout, Thomas J, additional, and Loibl, Sibylle, additional

Published
2024
Full Text
View/download PDF

2. A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease...

Author

Chan, Hoi Wai, Tse, Chris Chun Long, Li, Yu-Chung, Leung, Roland Ching-Yu, Wong, Jeffrey Sum Lung, Kwok, Gin Wai, Li, Hoi Lam, Tsang, Wing Yan Josephine, Li, Cho Wing, Lo, Jenny WY, Tang, Vikki, Hui, Rina, Yau, Thomas, Ho, James CM, and Chiu, Joanne W

Published
2024
Full Text
View/download PDF

5. Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma

Author

Cheung, Tan-To, primary, Ho, Daniel Wai-Hung, additional, Lyu, Shirley Xueying, additional, Zhang, Qingyang, additional, Tsui, Yu-Man, additional, Yu, Tiffany Ching-Yun, additional, Sze, Karen Man-Fong, additional, Lee, Joyce Man-Fong, additional, Lau, Vince Wing-hang, additional, Chu, Edward Yin-Lun, additional, Tsang, Simon Hing-Yin, additional, She, Wong-Hoi, additional, Leung, Roland Ching-Yu, additional, Yau, Thomas Chung-Cheung, additional, and Ng, Irene Oi-Lin, additional

Published
2023
Full Text
View/download PDF

6. Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma

Author

Cheung, Tan-To, Ho, Daniel Wai-Hung, Lyu, Shirley Xueying, Zhang, Qingyang, Tsui, Yu-Man, Yu, Tiffany Ching-Yun, Sze, Karen Man-Fong, Lee, Joyce Man-Fong, Lau, Vince Wing-hang, Chu, Edward Yin-Lun, Tsang, Simon Hing-Yin, She, Wong-Hoi, Leung, Roland Ching-Yu, Yau, Thomas Chung-Cheung, and Ng, Irene Oi-Lin

Abstract

Introduction:Immunotherapy has resulted in pathologic responses in hepatocellular carcinoma (HCC), but the benefits and molecular mechanisms of neoadjuvant immune checkpoint blockade are largely unknown. Methods:In this study, we evaluated the efficacy and safety of preoperative nivolumab (anti-PD-1) in patients with intermediate and locally advanced HCC and determined the molecular markers for predicting treatment response. Results:Between July 2020 and November 2021, 20 treatment-naive HCC patients with intermediate and locally advanced tumors received preoperative nivolumab at 3 mg/kg for 3 cycles prior to surgical resection. Nineteen patients underwent surgical resection on trial. Seven (36.8%) of the 19 patients had major pathologic tumor necrosis (≥60%) in the post-nivolumab resection specimens, with 3 having almost complete (>90%) tumor necrosis. The tumor necrosis was hemorrhagic and often accompanied by increased or dense immune cell infiltrate at the border of the tumors. None of the patients developed major adverse reactions contradicting hepatectomy. RNA-sequencing analysis on both pre-nivolumab tumor biopsies and post-nivolumab resected specimens showed that, in cases with major pathologic necrosis, the proportion of CD8 T cells in the HCC tissues predominantly increased after treatment. Moreover, to investigate noninvasive biomarker for nivolumab response, we evaluated the copy number variation (CNV) using target-panel sequencing on plasma cell-free DNA of the patients and derived a CNV-based anti-PD-1 score. The score correlated with the extent of tumor necrosis and was validated in a Korean patient cohort with anti-PD-1 treatment. Conclusion:Neoadjuvant nivolumab demonstrated promising clinical activity in intermediate and locally advanced HCC patients. We also identified useful noninvasive biomarker predicting responsiveness.

Published
2024
Full Text
View/download PDF

7. Consensus Statements on Precision Oncology in the China Greater Bay Area.

Author

Lam, Tai-Chung, Cho, William Chi-Shing, Au, Joseph Siu-Kie, Ma, Edmond Shiu-Kwan, Lam, Stephen Tak-Sum, Loong, Herbert Ho-Fung, Wong, Jason Wing Hon, Wong, S.N. Michael, Lee, Victor Ho-Fun, Leung, Roland Ching-Yu, Lau, Johnny Kin-Sang, Kam, Michael Tsz-Yeung, Mok, Florence Siu-Ting, Lim, Fiona Mei-Ying, Nyaw, Jonathan Shi-Feng, Tin, Winnie Wing-Yan, Cheung, Ka-Man, Chan, Oscar Siu-Hong, Kwong, Philip Wai-Kay, and Cheung, Foon-Yiu

Subjects
CLINICAL decision support systems, THERAPEUTICS, CANCER prognosis, PATIENT participation, ONCOLOGY
Abstract

BACKGROUND: Next-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA. METHODS: Thirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0. RESULTS: The POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice. CONCLUSION: POWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA. POWG consensus statements standardize genomic-based cancer care in the China GBA, enabling evidence-based practice and improved patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes

Author

Lui, David Tak Wai, primary, Lee, Chi Ho, additional, Tang, Vikki, additional, Fong, Carol Ho Yi, additional, Lee, Alan Chun Hong, additional, Chiu, Joanne Wing Yan, additional, Leung, Roland Ching Yu, additional, Kwok, Gerry Gin Wai, additional, Li, Bryan Cho Wing, additional, Cheung, Tan To, additional, Woo, Yu Cho, additional, Lam, Karen Siu Ling, additional, and Yau, Thomas, additional

Published
2021
Full Text
View/download PDF

10. Cabozantinib in advanced HCC patients previously treated with immune checkpoint inhibitors: A territory-wide cohort study.

Author

Wong, Jeffrey Sum Lung, primary, Dong, Yawen, additional, Tang, Vikki, additional, Leung, Thomas Wai-Tong, additional, Yeung, Cynthia SY, additional, Tai, Anna, additional, Law, Ada, additional, Shum, Tracy Cy, additional, Kwok, Gin Wai, additional, Li, Bryan, additional, Leung, Roland Ching-Yu, additional, Chiu, Joanne Wing Yan, additional, Ma, Ka Wing, additional, She, Wong-Hoi, additional, Tsang, Wing Yan Josephine, additional, Cheung, Tan To, additional, and Yau, Thomas, additional

Published
2021
Full Text
View/download PDF

11. Outcomes of tyrosine kinase inhibitors after immunotherapy in advanced hepatocellular carcinoma: A multi-center study.

Author

Yau, Thomas, primary, Lee, Joycelyn Jie Xin, additional, Wong, Jeffrey Sum Lung, additional, Tang, Vikki, additional, Chan, Jess, additional, Kwok, Gin Wai, additional, Chiu, Joanne Wing Yan, additional, Leung, Roland Ching-Yu, additional, Li, Bryan, additional, Tsang, Wing Yan Josephine, additional, Cheung, Tan To, additional, Choo, SuPin, additional, and Tai, Wai Meng David, additional

Published
2021
Full Text
View/download PDF

12. The use of cabozantinib in advanced hepatocellular carcinoma (HCC): Hong Kong multi-center experience.

Author

Dong, Yawen, primary, Leung, Thomas Wai-Tong, additional, Kwok, Gin Wai, additional, Tang, Vikki, additional, Li, Bryan, additional, Leung, Roland Ching-Yu, additional, Chiu, Joanne Wing Yan, additional, Wong, Jeffrey Sum Lung, additional, Ma, Ka Wing, additional, She, Wong Hoi, additional, Tsang, Wing Yan Josephine, additional, Cheung, Tan To, additional, and Yau, Thomas, additional

Published
2021
Full Text
View/download PDF

13. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.

Author

Wong, Jeffrey Sum Lung, primary, Kwok, Gin Wai, additional, Tang, Vikki, additional, Li, Bryan, additional, Leung, Roland Ching-Yu, additional, Chiu, Joanne Wing Yan, additional, Ma, Ka Wing, additional, She, Wong-Hoi, additional, Tsang, Wing Yan Josephine, additional, Cheung, Tan To, additional, and Yau, Thomas, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results